Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BCG-Refractory Bladder Cancer Clear all
Terminated Phase 2 Interventional Results available

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

NCT01732107
View directory record Official record
Conditions
Bladder Cancer
Interventions
Dovitinib
Drug
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Rockledge, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT02773849
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
ADSTILADRIN
Biological
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
34
States / cities
Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

NCT02202772
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
PF-06801591, Bacillus Calmette-Guerin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082
View directory record Official record
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
381
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

NCT04387461
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer
Interventions
CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
La Jolla, California • Orange, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

NCT03022825
View directory record Official record
Conditions
Bladder Cancer
Interventions
N-803 and BCG, N-803
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
28
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 25, 2026, 12:55 AM EDT
Recruiting Phase 1 Interventional

A Phase I Intravesical PPM Therapy for NMIBC

NCT05519241
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
PLZ4-coated paclitaxel-loaded micelles (PPM)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed No phase listed Observational

Retrospective Chart Review of Valstar

NCT01304173
View directory record Official record
Conditions
Carcinoma in Situ of Bladder
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

NCT04172675
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2Phase 3 Interventional

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

NCT00406068
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

NCT01259063
View directory record Official record
Conditions
Bladder Cancer
Interventions
Everolimus and Intravesical Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
TAR-200, Cetrelimab
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

NCT00003129
View directory record Official record
Conditions
Bladder Cancer
Interventions
valrubicin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
10
States / cities
Tampa, Florida • Urbana, Illinois • East Orange, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Nivolumab, BCG, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
25
States / cities
Los Angeles, California • Riverside, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

NCT01625260
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
ALT-801, Gemcitabine
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 25, 2026, 12:55 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1 Interventional

1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

NCT01162785
View directory record Official record
Conditions
Bladder Cancer
Interventions
SCH 721015
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 25, 2026, 12:55 AM EDT
Terminated Phase 3 Interventional

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

NCT03335059
View directory record Official record
Conditions
Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder, Cancer of the Bladder, Malignant Tumor of Urinary Bladder, Neoplasms, Bladder, Urinary Bladder Cancer, Carcinoma in Situ of Bladder, Papillary Carcinoma of Bladder (Diagnosis), BCG-Unresponsive Bladder Cancer
Interventions
Synergo® RITE + MMC
Combination Product
Lead sponsor
Medical Enterprises Ltd.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Hanover, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 3 Interventional

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

NCT00006034
View directory record Official record
Conditions
Bladder Cancer
Interventions
keyhole limpet hemocyanin, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Intracel
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 25, 2026, 12:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

NCT02009332
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
ABI-009, Gemcitabine
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 25, 2026, 12:55 AM EDT